Successful Adjunctive Treatment of a Severe Case of COVID-19 Associated Pulmonary Aspergillosis with Nebulized Liposomal Amphotericin B

Case Report

Austin Crit Care Case Rep. 2022; 6(1): 1039.

Successful Adjunctive Treatment of a Severe Case of COVID-19 Associated Pulmonary Aspergillosis with Nebulized Liposomal Amphotericin B

Seitz T1*, Mader T1, Morajda B2, Hoepler W1, Hind J1, Friese E1, Neuhold S1, Zoufaly A1,3, Wenisch C1, Kitzberger R1

¹Department of Infectious Diseases and Tropical Medicine, Klinik Favoriten, Vienna, Austria

²Department of Respiratory and Lung Diseases, Klinik Penzing, Vienna, Austria

³Faculty of Medicine, Sigmund Freud University, Vienna, Austria

*Corresponding author: Seitz T, Department of Infectious Diseases and Tropical Medicine, KundratstraΒe 3, 1100-Vienna, Austria

Received: May 02, 2022; Accepted: June 18, 2022; Published: June 25, 2022

Abstract

We report a case of a patient suffering from severe COVID-19 complicated by CAPA (COVID-19 associated pulmonary aspergillosis). Successful therapy with systemic voriconazole and isavuconazole failed, liposomal Amphotericin B was not possible due to acute renal failure. After nebulized Amphotericin was added to systemic isavuconazole, CAPA could be treated successfully.

Keywords: COVID-19; CAPA; Invasive Aspergillosis; Amphotericin B

Case Report

A 52-year-old woman, whose past medical history included obesity, arterial hypertension, diabetes mellitus II, peripheral arterial occlusive disease necessitating transtibial amputation, was admitted to the normal ward of our department of infectious diseases in July 2021 due to dyspnoea and fatigue for the last four days. An X-ray showed bilateral pneumonic infiltrations, the RT-PCR from a nasopharyngeal swab was SARS-CoV-2 positive (L452R und T478K, CT value 26. 1). The initial laboratory results showed normal white blood cell count (WBC) of 6 G/l with a 18% lymphocytes, an elevated C-reactive protein (CRP) of 131 mg/l and IL 6 of 284 pg/mL). Due to respiratory failure oxygen was administered via nasal cannula, however, one day later, the patient had to be transferred to the intensive care unit. Noninvasive ventilation was started, and an immunomodulating therapy with dexamethasone 20mg for 5 days, followed by 10mg for 5 days was given. Three days after hospital admission intubation and mechanical ventilation were necessary. A total five cycles of prone positioning were performed. Seven days after hospital admission inflammation parameterswere rising (WBC 16 G/L, CRP 344. 4 mg/l, IL 6 322 pg/ mL) and fever spiked up to 40°C. The X-ray showed a deterioration of the infiltrates. Piperacillin/Tazobactam was initiated empirically. Multiplex PCR of tracheal secretion detected no pathogen, and there was no growth in the blood cultures. A bronchoscopy showed white/greyish plaques in both main bronchi (see picture 1a). Galactomannan (GM) from bronchoalveolar lavage (BAL) was highly positive (ODI over the measurable value), and cultures grew Aspergillus fumigatus complex. Also, Beta-D-Glucan (BDG) from serum was highly positive (> 500pg/ml). A therapy with voriconazole (VOR) 6mg/kg bid on day 1, followed by 4mg/kg bid on day 2 was started. After three days therapy was switched to isavuconazole (ISA) (200 mg tid for two days, followed by 200 once daily) due acute renal failure and rising of liver function tests. Oral administration was not possible due massive regurgitation over the gastric tube. Initially,the inflammation parameters declined slightly. However, four days later the respiratory situation deteriorated, inflammation parameters increasedsharply (WBC 17 G/L, CRP 402. 7 mg/l, IL 6 340 pg/mL). A SARS-CoV-2 PCR of tracheal secretion repeatedly showed a CT value over 30, so a successful clearance of SARSCoV- 2 was assumed. Bronchoscopy 10 days after start of antifungal therapy macroscopically showed an impressive deterioration: Tracheobronchial ulcerations with pseudomembranes and white plaques were observed (see picture 1b). GM was again highly positive (ODI over the measurable value), aspergillus fumigatus complex grew in all cultures of BAL. A CT showed bilateral infiltrates (see picture 2), but there was no sign of caverns, organised pneumonia or pulmonary embolism. As the respiratory situation deteriorated further, prone positioning was started again. A tracheotomy was performed. The antimicrobial resistance testing showed susceptibility to ISA, VOR and Amphotericin B. Nebulizedliposomal Amphotericin B (lipAMB) (Ambisome®, Gilead) was added to intravenous ISA (inhalation over 30 minutes via a nebulizer of 25mg lipAMP attenuated with aqua). The nebulized therapy was tolerated well. GM of BAL decreased continuously (ODI 5. 4 after 6 days, ODI 3. 6 after 12 days and negative after 30 days of inhalative therapy). A bronchoscopy 30 days after initiation of inhaled therapy showed great improvement (Figure 1c). Weaning and mobilisation could be done successfully and decannulation was performed 55 days after hospital admission. The inflammation parameters decreased to normal values, the kidney parameters normalised. Inhaled lipAMB and intravenous ISA were stopped and oral VOR started (2x400mg once followed by 2x200mg for 8 weeks). The VORserum level was always within the range of 2-4 mcg/mL. BDG from serum decreased continuously (320 pg/ml after 38 days and 170 pg/ml after 45 days of antifungal therapy).